These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 22041109)

  • 1. Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
    Dubbelman AC; Rosing H; Jansen RS; Mergui-Roelvink M; Huitema AD; Koetz B; Lymboura M; Reyderman L; Lopez-Anaya A; Schellens JH; Beijnen JH
    Drug Metab Dispos; 2012 Feb; 40(2):313-21. PubMed ID: 22041109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
    Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
    Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism of patupilone in patients with advanced solid tumor malignancies.
    Kelly KR; Zollinger M; Lozac'h F; Tan E; Mita A; Waldmeier F; Urban P; Anand S; Wang Y; Swart P; Takimoto C; Mita M
    Invest New Drugs; 2013 Jun; 31(3):605-15. PubMed ID: 22918719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of [
    Pusalkar S; Plesescu M; Gupta N; Hanley M; Venkatakrishnan K; Wu JT; Xia C; Zhang X; Chowdhury S
    Cancer Chemother Pharmacol; 2018 Nov; 82(5):803-814. PubMed ID: 30128949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the absorption, metabolism and excretion of [¹⁴C]pasireotide in healthy volunteers using accelerator mass spectrometry.
    Lin TH; Hu K; Flarakos J; Sharr-McMahon M; Mangold JB; He H; Wang Y
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):181-8. PubMed ID: 23680921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the Pharmacokinetics and Mass Balance of a Single Oral Dose of Trofinetide in Healthy Male Subjects.
    Darwish M; Nunez R; Youakim JM; Robertson P
    Clin Drug Investig; 2024 Jan; 44(1):21-33. PubMed ID: 38017349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
    Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers.
    James A; Blumenstein L; Glaenzel U; Jin Y; Demailly A; Jakab A; Hansen R; Hazell K; Mehta A; Trandafir L; Swart P
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):751-60. PubMed ID: 26254025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects.
    Chen N; Wen L; Lau H; Surapaneni S; Kumar G
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):789-97. PubMed ID: 22037879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of absorption, distribution, metabolism, and excretion of [
    Liao M; Watkins S; Nash E; Isaacson J; Etter J; Beltman J; Fan R; Shen L; Mutlib A; Kemeny V; Pápai Z; van Tilburg P; Xiao JJ
    Invest New Drugs; 2020 Jun; 38(3):765-775. PubMed ID: 31250355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry.
    Graham RA; Lum BL; Morrison G; Chang I; Jorga K; Dean B; Shin YG; Yue Q; Mulder T; Malhi V; Xie M; Low JA; Hop CE
    Drug Metab Dispos; 2011 Aug; 39(8):1460-7. PubMed ID: 21602311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer.
    Baker SD; Wirth M; Statkevich P; Reidenberg P; Alton K; Sartorius SE; Dugan M; Cutler D; Batra V; Grochow LB; Donehower RC; Rowinsky EK
    Clin Cancer Res; 1999 Feb; 5(2):309-17. PubMed ID: 10037179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, Mass Balance, and Biotransformation of [
    Ni S; Ma S; Yu Y; Yu Z; Zhu Y; Sun X; Li L; Sun C; Wang H; Peng P; Gu Z; Zhang H; Wu F; Miao L; Fan J
    Drugs R D; 2024 Sep; 24(3):465-476. PubMed ID: 39231890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
    Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
    Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
    Devriese LA; Witteveen PO; Marchetti S; Mergui-Roelvink M; Reyderman L; Wanders J; Jenner A; Edwards G; Beijnen JH; Voest EE; Schellens JH
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):823-32. PubMed ID: 23010853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
    Bello CL; Smith E; Ruiz-Garcia A; Ni G; Alvey C; Loi CM
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):379-85. PubMed ID: 23760812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
    Paci A; Rezai K; Deroussent A; De Valeriola D; Re M; Weill S; Cvitkovic E; Kahatt C; Shah A; Waters S; Weems G; Vassal G; Lokiec F
    Drug Metab Dispos; 2006 Nov; 34(11):1918-26. PubMed ID: 16896064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism and excretion of ropivacaine in humans.
    Halldin MM; Bredberg E; Angelin B; Arvidsson T; Askemark Y; Elofsson S; Widman M
    Drug Metab Dispos; 1996 Sep; 24(9):962-8. PubMed ID: 8886605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination pathways of [14C]losoxantrone in four cancer patients.
    Joshi AS; Pieniaszek HJ; Vokes EE; Vogelzang NJ; Davidson AF; Richards LE; Chai MF; Finizio M; Ratain MJ
    Drug Metab Dispos; 2001 Feb; 29(2):96-9. PubMed ID: 11159796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.